Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases. Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect. We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2007.10.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thrombolytic efficacy and safety of recombinant scu-PA in a rabbit retinal vein occlusion model.
Eur J Pharmacol
January 2025
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital. Electronic address:
Retinal vein occlusion (RVO) has become the second most common retinal vascular disease after diabetic retinopathy. Existing therapeutic approaches, including intravitreal injection of antivascular endothelial growth factors (anti-VEGFs) and/or glucocorticoids and laser therapy, primarily address secondary macular edema and neovascularisation. However, these strategies do not address the underlying cause of the disease and may have harmful side effects.
View Article and Find Full Text PDFArctiin suppress Th17 cells response and ameliorates experimental autoimmune uveitis through JAK/STAT signaling.
Cell Immunol
January 2025
Department of Rheumatology, Jincheng People 's Hospital, Shanxi Province, China.
Conventional treatments for autoimmune uveitis, such as corticosteroids and systemic immunosuppressants, often result in adverse side effects, prompting the need for therapies targeting specific molecular pathways. This study investigates the effects of Arctiin, known for its diverse biological properties, on experimental autoimmune uveitis (EAU) through its action on Th17 cells and the JAK/STAT signaling pathway. Our findings reveal that Arctiin significantly alleviates EAU by reducing clinical scores, inflammatory cell infiltration, and levels of inflammatory cytokines like IL-17 and TNF-α in the eye.
View Article and Find Full Text PDFAn update on ocular effects of anti-diabetic medications.
Surv Ophthalmol
January 2025
University of Pittsburgh, School of Medicine, PA, USA. Electronic address:
The global increase in the prevalence of type 2 diabetes has led to the development and implementation of new classes of anti-diabetic medications, introducing advanced therapeutic options for the management of the disease. These new medications, though primarily designed to regulate blood glucose levels, also have applications in weight management, potentially transforming the current approaches to diabetes treatment. Newer medications, however, have ophthalmic side effects with controversies in trials and real-life data.
View Article and Find Full Text PDFLorlatinib Induced Blindness: A Rare Entity.
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey. Electronic address:
Lorlatinib is a central nervous system (CNS) penetrant third generation tyrosine kinase inhibitor (TKI) approved for the first line management of metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) rearrangement [1] which accounts for 3-5% of NSCLC cases [2]. The most commonly reported side effects include hyperlipidemia, edema, peripheral neuropathy and CNS effects [2]. While ocular side effects such as photopsia, blurred vision, vitreous floaters and diplopia have been documented with another ALK TKI, crizotinib, there are few reports of such effects with lorlatinib [3].
View Article and Find Full Text PDFDynamic Accommodation Responses in Subjects Wearing Myopia Control Spectacles Modifying Peripheral Refraction.
Invest Ophthalmol Vis Sci
January 2025
Laboratorio de Óptica, Universidad de Murcia, Campus de Espinardo, Murcia, Spain.
Purpose: Peripheral optics have been suggested to play a role in myopia progression, with accommodation responses also considered a potential contributor. This study aimed to investigate whether modifications in peripheral optics through different spectacle lenses affect accommodation responses.
Methods: Dynamic accommodation responses were assessed using a double-pass instrument while switching the target from distance (3 m for 3 seconds) to near (0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!